Fig. 5

The numbers of peripheral basophils, tumor-infiltrating basophils, and M2 macrophages in patients treated with the neoadjuvant anti-PD-1 inhibitor plus chemotherapy combination. a Representative immunohistochemical images of consecutive paraffin sections of primary tumors post-neoadjuvant anti-PD-1 inhibitor plus chemotherapy stained with hematoxylin/eosin (HE), anti-ProMBP1, and anti-CD163 antibodies in responders and non-responders. Scale bar, 50 μm. b The peripheral basophils, tumor-infiltrating basophils, and M2 macrophage counts from responders and non-responders. Responders were characterized by tumor regression of grades 0–1. PD-1, programmed death-1. Quantitative data are presented as the mean ± SEM. *P < .05. **P < .01. ***P < .001